Scott Ackler

3.9k total citations
10 papers, 625 citations indexed

About

Scott Ackler is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Scott Ackler has authored 10 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Genetics. Recurrent topics in Scott Ackler's work include Cancer therapeutics and mechanisms (3 papers), Cell death mechanisms and regulation (3 papers) and Cancer-related Molecular Pathways (3 papers). Scott Ackler is often cited by papers focused on Cancer therapeutics and mechanisms (3 papers), Cell death mechanisms and regulation (3 papers) and Cancer-related Molecular Pathways (3 papers). Scott Ackler collaborates with scholars based in United States and United Kingdom. Scott Ackler's co-authors include Anatol Oleksijew, Steven W. Elmore, Michael J. Mitten, Saul H. Rosenberg, David J. Frost, Kelly Foster, Christin Tse, Stephen W. Fesik, Marion Refici and Christopher A. Tobias and has published in prestigious journals such as Blood, Oncogene and Clinical Cancer Research.

In The Last Decade

Scott Ackler

10 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Ackler United States	8	472	233	94	76	75	10	625
Cathy E. Nolan United States	6	384 0.8×	206 0.9×	117 1.2×	113 1.5×	68 0.9×	8	585
Kelly Foster United States	8	285 0.6×	180 0.8×	63 0.7×	62 0.8×	68 0.9×	10	444
Patrick M. Brauer United States	15	424 0.9×	246 1.1×	51 0.5×	65 0.9×	106 1.4×	23	606
Gary Borzillo United States	12	492 1.0×	169 0.7×	93 1.0×	93 1.2×	147 2.0×	24	737
Jiahuai Tan United States	8	548 1.2×	165 0.7×	52 0.6×	67 0.9×	41 0.5×	16	687
Margherita Corbo United Kingdom	7	433 0.9×	166 0.7×	51 0.5×	82 1.1×	58 0.8×	9	599
A M Martelli Italy	10	580 1.2×	191 0.8×	58 0.6×	91 1.2×	89 1.2×	17	785
Shengyan Xiang United States	16	765 1.6×	273 1.2×	61 0.6×	48 0.6×	58 0.8×	25	919
Cory Mavis United States	16	441 0.9×	285 1.2×	245 2.6×	159 2.1×	120 1.6×	74	754
Kristina West United States	9	646 1.4×	187 0.8×	80 0.9×	87 1.1×	69 0.9×	12	819

Countries citing papers authored by Scott Ackler

Since Specialization

Citations

This map shows the geographic impact of Scott Ackler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Ackler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Ackler more than expected).

Fields of papers citing papers by Scott Ackler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Ackler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Ackler. The network helps show where Scott Ackler may publish in the future.

Co-authorship network of co-authors of Scott Ackler

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Ackler. A scholar is included among the top collaborators of Scott Ackler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Ackler. Scott Ackler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Ackler, Scott, Anatol Oleksijew, Jun Chen, et al.. (2015). Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclax. Pharmacology Research & Perspectives. 3(5). e00178–e00178. 21 indexed citations

2.

Ackler, Scott, et al.. (2012). Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo. British Journal of Pharmacology. 167(4). 881–891. 33 indexed citations

3.

Chen, Jun, Sha Jin, Xiaoli Huang, et al.. (2011). The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo. Molecular Cancer Therapeutics. 10(12). 2340–2349. 119 indexed citations

4.

Ackler, Scott, Michael J. Mitten, Kelly Foster, et al.. (2010). The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemotherapy and Pharmacology. 66(5). 869–880. 100 indexed citations

5.

Hickson, Jonathan A., Scott Ackler, Dieter H. Klaubert, et al.. (2010). Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin. Cell Death and Differentiation. 17(6). 1003–1010. 50 indexed citations

6.

Ackler, Scott, Xiao Yu, Michael J. Mitten, et al.. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7(10). 3265–3274. 64 indexed citations

7.

Shoemaker, Alex R., Michael J. Mitten, Jessica Adickes, et al.. (2008). Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models. Clinical Cancer Research. 14(11). 3268–3277. 155 indexed citations

8.

Shoemaker, Alex R., Michael J. Mitten, Anatol Oleksijew, et al.. (2006). The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma.. Blood. 108(11). 825–825. 2 indexed citations

9.

Ackler, Scott, Shakeel Ahmad, Christopher A. Tobias, Michael D. Johnson, & Robert I. Glazer. (2002). Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene. 21(2). 198–206. 78 indexed citations

10.

Ackler, Scott, Shakeel Ahmad, Christopher A. Tobias, Michael D. Johnson, & Robert I. Glazer. (2002). Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene. 21(2). 198–206. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact